<DOC>
	<DOCNO>NCT00537667</DOCNO>
	<brief_summary>The purpose study compare IL-1ra combination IL-1ra PEGsTNF-RI respect ability reduce inflammation bone cartilage destruction synovium subject rheumatoid arthritis .</brief_summary>
	<brief_title>The SPECTRA Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Diagnosed RA determine American College Rheumatology ( ACR ) criterion ( Appendix C ) Disease duration le 12 week diagnosis confirm physician source documentation Disease duration &lt; 10 year Active RA baseline define minimum 6 swollen joint 9 tender/painful joint ( base 66/68joint count exclude distal interphalangeal joint ) screen baseline , And Creactive protein ( CRP ) &gt; 2 mg/dL screening . Have active clinical synovitis knee determine investigator base clinical evaluation 18 year age old Men nonpregnant ( negative serum HCG screening unless surgically sterile postmenopausal ) , nonbreastfeeding woman may enrol . Females childbearing potential male must use adequate contraceptive precaution determine principal investigator . Subjects take DMARD less 3 month must take DMARDs within 4 week prior screen . Subjects take DMARD long 3 month must take DMARDs within 6 month screen . Subject 's dos NSAIDs oral corticosteroid ( 10 mg/day prednisone equivalent ) must keep stable 4 week screen Subjects must intrarticular injection joint arthroscoped least 3 month prior screen . Before study specific procedure screen do , subject legally acceptable representative must give informed consent participation study ( see Section 12.2 ) . Before buccal smear blood sample take genetic testing , subject legally acceptable representative must give informed consent use sample genetic testing ( see Section 12.2 ) . ACR functional class IV American Rheumatology Association anatomical stage IV ( see Appendix C ) Disease duration &gt; 10 year Diagnosed follow : Felty 's syndrome Advanced uncontrolled Diabetes Mellitus ( define : HbA1c &gt; 8 % , peripheral neuropathy , renal/retinal involvement , vascular disorder ) Malignancy , basal cell carcinoma skin situ carcinoma cervix , within past five year Any major chronic inflammatory disease syndrome ( e.g. , psoriatic arthritis , spondyloarthropathy , inflammatory bowel disease , fibromyalgia require treatment last year ) Any uncontrolled , clinically significant systemic disease Preexisting recent onset central nervous system demyelinate disorder Significant hematologic abnormalities A history drug alcohol abuse within previous 24 week Known hepatitis B surface antigen , hepatitis C virus Human Immunodeficiency Virus positive Any disorder compromise ability give inform consent participation study Is expect require major surgical operation study would interfere collection require assessment . Has infection require systemic antiinfective therapy , open wound , develop frequent acute chronic infection past 12 week . Prior active tuberculosis . Total white blood cell count &lt; 3.5 x 109/L screen Neutrophil count &lt; 2.5 x 109/L screen Platelet count &lt; 125 x 109/L screen Hemoglobin &lt; 8.0 g/dL screen Abnormal liver function test ( AST/ALT &gt; 1.5 x upper limit normal ) screen Abnormal renal function ( serum creatinine &gt; 1.5 x upper limit normal ) screen Prior treatment proteinbased TNF inhibitor ( e.g . etanercept , infliximab , PEG sTNFRI , D2E7 ) Prior treatment anakinra Receiving receive investigational drug within previous 16 week within least 5 halflives investigational drug , whichever great ( currently use investigational device ) Received intraarticular injection ( e.g.. corticosteroid , hyaluronate preparation ) systemic corticosteroid injection within 4 week screen visit Requires analgesia paracetamol , NSAIDs , codeine , oxycodone , propoxyphene , tramadol , hydrocodone , combination product ( equivalent ) Subject ( men woman childbearing potential ) use adequate contraceptive precaution determine principal investigator Known allergy E coliderived product Not available followup assessment Concerns subject 's compliance protocol procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>IL-1ra</keyword>
	<keyword>PEG sTNF-RI</keyword>
	<keyword>Synovial biopsy</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Bone Cartilage Destruction</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>